Skip to main content Skip to footer
American Family Children's Hospital
SHARE TEXT
 


Print Friendly Page

Protocol No. ANBL1232

Principal Investigator DeSantes, Kenneth

Phase III

Age Group Children

Scope National

Sponsor Type National

Title Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma


Applicable Disease Sites Neuroblastoma

Therapies Involved Cytotoxic Chemotherapy; Surgery

Drugs Involved adr (doxorubicin); adria (doxorubicin); adriamycin (doxorubicin); carboplatin; cbdca (carboplatin); cpm (cyclophosphamide); ctx (cyclophosphamide); cyclophosphamide; cytoxan (cyclophosphamide); dox (doxorubicin); doxorubicin; etoposide; filgrastim; g-csf (filgrastim); gcsf (filgrastim); neosar (cyclophosphamide); neupogen (filgrastim); paraplatin (carboplatin); vepesid (etoposide); vp-16 (etoposide)

Status Open

Participating Institutions Gundersen Health System; UW Hospital and Clinics